Antidepressants versus placebo for generalised anxiety disorder (GAD)
References
Additional references
Alegria AA, Hasin DS, Nunes EV, Liu S, Davies C, Grant BF, et al. Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 2010;71(9):1187‐95.
Angst J, Vollrath M. The natural history of anxiety disorders. Acta Psychiatrica Scandinavica 1991;84(5):446‐52. [PUBMED: 1776498]
Angst J, Gamma A, Baldwin DS, Ajdacic‐Gross V, Rössler W. The generalized anxiety spectrum: prevalence, onset, course and outcome. European Archives of Psychiatry and Clinical Neuroscience 2009;259(1):37‐45. [PUBMED: 18575915]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ‐ DSM‐III. 3rd Edition. Washington, DC: American Psychiatric Association, 1980.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ‐ DSM‐III‐R. 3rd Edition. Washington, DC: American Psychiatric Association, 1987.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ‐ DSM‐IV. 4th Edition. Washington, DC: American Psychiatric Association, 1994.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 2000.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Washington, DC: American Psychiatric Association, 2013.
Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta‐analysis. BMJ (Clinical research ed.) 2011;342:d1199. [PUBMED: 21398351]
Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S. An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World Journal of Biological Psychiatry 2012;13(7):510‐6. [DOI: 10.3109/15622975.2011.624548]
Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence‐based pharmacological treatment of anxiety disorders, post‐traumatic stress disorder and obsessive‐compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology 2014;28(5):403‐39.
Briley M, Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clinical Neuropharmacology 1993;16(5):387‐400.
Chessick CA, Allen MH, Thase ME, Batista Miralha da Cunha A, Kapczinski F, Silva de Lima M, et al. Azapirones for generalized anxiety disorder. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006115]
Covin R, Ouimet AJ, Seeds PM, Dozois DJ. A meta‐analysis of CBT for pathological worry among clients with GAD. Journal of Anxiety Disorders 2008;22(1):108‐16. [PUBMED: 17321717]
Depping AM, Komossa K, Kissling W, Leucht S. Second‐generation antipsychotics for anxiety disorders. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD008120.pub2; PUBMED: 21154392]
Divine G, Brown J, Frazier L. The unit of analysis error in studies about physicians’ patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9.
Doron R, Lotan D, Versano Z, Benatav L, Franko M, Armoza S, Kately N, Rehavi M. Escitalopram or novel herbal mixture treatments during or following exposure to stress reduce anxiety‐like behavior through corticosterone and BDNF modifications. PLoS One 2014;9(4):e91455.
Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta‐analyses. International Clinical Psychopharmacology 2005;20(1):49‐52. [PUBMED: 15602117]
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7‐10. [PUBMED: 16360555]
Gale CK, Millichamp J. Generalised anxiety disorder. BMJ Clinical Evidence 2011;2011:pii: 1002. [PUBMED: 22030083]
Gale C, Herbison P, Glue P, Coverdale J, Guaiana G. Benzodiazepines for generalised anxiety disorder (GAD). Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD001846.pub3]
Gonçalves DC, Byrne GJ. Interventions for generalized anxiety disorder in older adults: systematic review and meta‐analysis. Journal of Anxiety Disorders 2012;26(1):1‐11. [PUBMED: 21907538]
McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 16 October 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Graeff FG, Zangrossi H. The dual role of serotonin in defense and the mode of action of antidepressants on generalized anxiety and panic disorders. Central Nervous System Agents in Medicinal Chemistry 2010;10(3):207‐17.
Grant BF, Hasin DS, Stinson FKS, Dawson DA, June RW, Goldstein RB, et al. Prevalence, correlates, co‐morbidity, and comparative disability of DSM‐IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychological Medicine 2005;35(12):1747‐59.
Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD006815.pub2; PUBMED: 21154375]
Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology ‐ Revised (DHEW Publ No ADM 76‐338). Rockville, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:218‐22.
Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32(1):50‐5. [PUBMED: 13638508]
Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hofmann SG, Smits JA. Cognitive‐behavioral therapy for adult anxiety disorders: a meta‐analysis of randomized placebo‐controlled trials. Journal of Clinical Psychiatry 2008;69(4):621‐32. [PUBMED: 18363421]
Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD001848.pub4; PUBMED: 17253466]
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive‐compulsive disorders. BMC Psychiatry 2014;14(Suppl 1):S1. [DOI: 10.1186/1471‐244X‐14‐S1‐S1]
Kujanpää T, Ylisaukko‐Oja T, Jokelainen J, Hirsikangas S, Kanste O, Kyngäs H, et al. Prevalence of anxiety disorders among Finnish primary care high utilizers and validation of Finnish translation of GAD‐7 and GAD‐2 screening tools. Scandinavian Journal of Primary Health Care 2014;32(2):78‐83.
LaLonde CD, Van Lieshout RJ. Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta‐analysis. Journal of Clinical Psychopharmacology 2011;31(3):326‐33. [PUBMED: 21508847]
Lim L, Ng TP, Chua HC, Chiam PC, Won V, Lee T, et al. Generalised anxiety disorder in Singapore: prevalence, co‐morbidity and risk factors in a multi‐ethnic population. Social Psychiatry and Psychiatric Epidemiology 2005;40(12):972‐9.
Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off‐label uses in adults: a systematic review and meta‐analysis. JAMA 2011;306(12):1359‐69. [PUBMED: 21954480]
Merikangas KR, He J, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication‐‐Adolescent Supplement (NCS‐A). Journal of the American Academy of Child and Adolescent Psychiatry 2010;49(10):980‐9.
Mitte K, Noack P, Steil R, Hautzinger M. A meta‐analytic review of the efficacy of drug treatment in generalized anxiety disorder. Journal of Clinical Pharmacology 2005;25(2):141‐50.
Miyasaka LS, Atallah AN, Soares BG. Valerian for anxiety disorders. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD004515.pub2; PUBMED: 17054208]
Otte C. Cognitive behavioral therapy in anxiety disorders: current state of the evidence. Dialogues in Clinical Neuroscience 2011;13(4):413‐21. [PUBMED: 22275847]
Revicki DA, Travers K, Wyrwich KW, Svedsäter H, Locklear J, Mattera MS, et al. Humanistic and economic burden of generalized anxiety disorder in North America and Europe. Journal of Affective Disorders 2012;140(2):103‐12.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Reinhold JA, Mandos LA, Rickels K, Lohoff FW. Pharmacological treatment of generalized anxiety disorder. Expert Opinion on Pharmacotherapy 2011;12(16):2457‐67.
Romera I, Fernández‐Pérez S, Montejo AL, Caballero F, Caballero L, Arbesú JÁ, et al. Generalized anxiety disorder, with or without co‐morbid major depressive disorder, in primary care: prevalence of painful somatic symptoms, functioning and health status. Journal of Affective Disorders 2010;127(1‐3):160‐8. [PUBMED: 20541811]
Samuel M, Zimovetz EA, Gabriel Z, Beard SM. Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review. International Cinical Psychopharmacology 2011;26(2):63‐8. [PUBMED: 21088608]
Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Australian and New Zealand Journal of Psychiatry 2011;45(1):27‐35. [PUBMED: 21073405]
Schatzberg A, DeBattista C. Manual of Clinical Psychopharmacology. Washington D.C.: Americal Psychiatric Publishing, 2015.
Schmitt R, Gazalle FK, Lima MS, Cunha A, Souza J, Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta‐analysis. Revista Brasileira de Psiquatria 2005;27(1):18‐24. [DOI: 10.1002/14651858.CD003592; PUBMED: 12804478]
Serrano‐Blanco A, Palao DJ, Luciano JV, Pinto‐Meza A, Luján L, Fernández A, et al. Prevalence of mental disorders in primary care: results from the diagnosis and treatment of mental disorders in primary care study (DASMAP). Social Psychiatry and Psychiatric Epidemiology 2010;45(2):201‐10.
Termorshuizen F, Palmen SJ, Heerdink ER. Suicide behavior before and after the start with antidepressants: a high persistent risk in the first month of treatment among the young. International Journal of Neuropsychopharmacology 2015;19(2):pii: pyv081. [DOI: 10.1093/ijnp/pyv081]
Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 2006;368(9553):2156‐66.
World Health Organization. The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD‐9). Geneva: World Health Organization, 1978.
World Health Organization. The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD‐10). Geneva: World Health Organization, 1992.
Wittchen H. Generalized anxiety disorder: prevalence, burden, and cost to society. Depression and Anxiety 2002;16(4):162‐71.
Wolk SI, Horwath E, Goldstein RB, Wickramaratne P, Weissman MM. Comparison of RDC, DSM‐III, DSM‐III‐R diagnostic criteria for generalized anxiety disorder. Anxiety 1996;2(2):71‐9. [PUBMED: 9160604]
